Atea secures up to $200M credit facility from Hercules Capital
What's the deal? Atea Pharmaceuticals, a late-stage clinical biopharmaceutical company developing oral antiviral therapies, has entered a credit facility of up to $200 million with Hercules CapitalDealroom has a profile for this one. Try Dealroom →. Atea received $65 million at closing, with the rest conditional on clinical, regulatory, and commercial milestones and lender approval.
What's the endgame? The non-dilutive financing supports Atea as it prepares to commercialise its bemnifosbuvir/ruzasvir (BEM/RZR) regimen for chronic hepatitis C virus (HCV) in the US, pending approval, and advances its hepatitis E programme. The facility has a 60-month maturity with a 48-month interest-only period.
Why now? The deal follows positive Phase 3 C-BEYOND results, which showed an eight-week BEM/RZR course for patients without cirrhosis was non-inferior to Epclusa. Atea expects topline data from its second Phase 3 trial, C-FORWARD, in early 2027, with a US new drug application planned for mid-2027.
Atea held $219.5 million in cash, cash equivalents, and investments as of June 30, 2026. With the initial $65 million draw, it expects to fund operations into mid-2028, supporting a potential 2028 launch without issuing equity.
What could go wrong? Most of the facility is not immediately available: up to $35 million hinges on a clinical milestone, up to $70 million on regulatory and commercial milestones, and a further $30 million is at the lenders' sole discretion. Access therefore depends on confirmatory trial results and FDA approval.
What they said: "This non-dilutive financing enhances our financial flexibility, while preserving a disciplined approach to capital deployment," said chief executive officer and founder Jean-Pierre Sommadossi. Hercules Capital's R. Bryan Jadot said the firm was "pleased to provide a flexible financing solution."
Morgan Stanley served as exclusive financial advisor to Atea on the facility.
The signal: The structure shows how late-stage biopharma firms are using milestone-linked debt to bridge toward regulatory and commercial catalysts while avoiding dilution—capital that unlocks only as the science delivers.
Read more: markets.financialcontent.com
Image credit: Generated with Gemini
